The AstraZeneca (LSE:AZN) share price is down 13% over 12 months. That’s not good. But it’s surpassed by GSK (LSE:GSK), which has experienced a 21% drop. In short, it’s not been a particularly auspicious year for the British pharmaceutical and biotech giants.

But which is the best deal for investors? I’m going to look at four popular metrics to give me a better idea.

1. Price-to-earnings

The price-to-earnings (P/E) ratio shows how much investors are willing to pay for each pound of a company’s earnings. AstraZeneca starts at 23.1 times in 2025 and gradually falls to 16.6 times by 2027. This indicates the market expects solid growth from AstraZeneca.

GSK, on the…